<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090527</url>
  </required_header>
  <id_info>
    <org_study_id>199210</org_study_id>
    <nct_id>NCT05090527</nct_id>
  </id_info>
  <brief_title>Penicillin Allergy Delabeling Project</brief_title>
  <acronym>PenProv</acronym>
  <official_title>Penicillin Delabeling With Help of a Risk Stratification Tool, Advanced Provocation Tests in a Non Allergologic Unit and Examination of the Gut Microbiota in Patients Labeled Penicillin Allergic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Forde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A investigational study to establish:&#xD;
&#xD;
        1. A validated risk stratification tool for patients labeled Penicillin allergic.&#xD;
&#xD;
        2. Facilitate provocation test for delabeling of Penicillin allergy outside an allergologic&#xD;
           clinic&#xD;
&#xD;
        3. Examine the gut microbiome of penicillin allergic patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients labeled penicillin allergic is a significant and growing public health problem. 10%&#xD;
      of all patients report penicillin allergy. 9 out of 10 however tolerate penicillin on&#xD;
      provocation, To be labeled as penicillin allergic has several well documented negative health&#xD;
      outcomes for the individual, and on a public health scale.&#xD;
&#xD;
      One of the biggest obstacles in delabeling penicillin allergy is the lack of validated tools&#xD;
      i Norwegian, the lack of in vitro tests for severe late /T cell mediated reactions and the&#xD;
      accessibility of the gold standard procedure, drug provocation test.&#xD;
&#xD;
      In this study patients having a penicillin allergy label will after giving their written&#xD;
      concent be screened used a risk stratification tool. The low risk patient will then directly&#xD;
      undergo a single full dose amoxicillin challenge. High risk patients are refered to a&#xD;
      allergologic clinic and undergoes full allergologic examination. The investigators seek to&#xD;
      document that in low risk patients is a single dose Amoxicillin challenge safe and beneficial&#xD;
      outside an allergologic clinic, and to validate the risk stratification tool in Norwegian.&#xD;
&#xD;
      The investigators want to examine the gut microbiome of patients labeled penicillin allergic.&#xD;
      Changes in the gut microbiome can be temporarily and permanent, and selected microbiome&#xD;
      profiles has shown to influence the health outcome of patients. Little is known about the&#xD;
      impact on the gut microbiome in patients labeled penicillin allergic and the examinators seek&#xD;
      to examine this, and correlate data with known risk profiles in gut microbiome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Entry criteria: Penicillin allergy noted in patients journal or patient reported.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None, open provocation test with amoxicillin for eligible patients after risk stratification with a questionnaire.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Validating of a risk stratification tool ( in Norwegian) and advanced drug provocation challenge</measure>
    <time_frame>trough study completion up to 3 years</time_frame>
    <description>Negative predictive value of the risk stratification tool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analyzing the effects of risk stratification and advanced drug provocation</measure>
    <time_frame>Trough study completion up to 5 years</time_frame>
    <description>Change in number of patients with antibiotic treatment in line with government recommendation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analyzing the gut microbiome of patient labeled penicillin allergic</measure>
    <time_frame>through study completion up to 3 years</time_frame>
    <description>Map the gut microbiota profile in patients labeled penicillin allergic with 16S rRibosomal ribonucleic acid sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in days submitted to hospital before and after delabeling in the current ward.</measure>
    <time_frame>Through study completion up to 3 years</time_frame>
    <description>number of days submittet to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related adverse events on oral provocation testing.</measure>
    <time_frame>trough study completion up to 3 years</time_frame>
    <description>number of patients with treatment related adverse event on oral provocation testing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Penicillin Allergy</condition>
  <arm_group>
    <arm_group_label>Directly delabeled trough risk stratification tool</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are stratified as &quot; no penicillin allergy&quot; undergo a one dose full dose provocation test with 500 mg amoxicillin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low risk patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients stratified as low risk on penicillin provocation undergo a one dose full dose provocation test with 500mg amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient stratified as high risk undergo a full allergologic work up, and only some of these will undergo a provocation test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Risk stratification</intervention_name>
    <description>advanced penicillin challenge after risk stratification</description>
    <arm_group_label>Directly delabeled trough risk stratification tool</arm_group_label>
    <arm_group_label>High risk</arm_group_label>
    <arm_group_label>Low risk patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Penicillin allergy in the patient journal oder patient reported&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able to give concent. Under 16 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torgeir Storaas, phd</last_name>
    <role>Study Chair</role>
    <affiliation>Regionalt senter for astma, allergi og annen overfølsomhet i Helse vest, Haukeland universitetssjukehus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Alnæs</last_name>
    <phone>55 97 50 00</phone>
    <email>marie.bjorbak.alnes@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Torgeir Storaas, phd</last_name>
    <phone>55 97 50 00</phone>
    <email>torgeir.storaas@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Alnæs</last_name>
      <phone>55 97 50 00</phone>
      <email>marie.bjorbak.alnes@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Marie Alnæs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Sandven</last_name>
      <email>lars.sandven@helse-forde.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

